QNCX

Insider Trades

Name	Value	Action	Price	Current Price
Benatti LucaDirector $174k50k shares SellDec 26, 2025 $3.47 --
Thye DirkDirector, Officer: CEO AND CHIEF MEDICAL OFFICER $54k77k shares BuyAug 30, 2024 $0.70 --
Thye DirkDirector, Officer: CEO AND CHIEF MEDICAL OFFICER $53k77.5k shares BuyAug 29, 2024 $0.69 --
Hannah BrendanCHIEF BUSINESS OFFICER AND COO $3.1k5k shares BuyAug 21, 2024 $0.62 --
Hannah BrendanCHIEF BUSINESS OFFICER AND COO $1.4k2.3k shares BuyAug 21, 2024 $0.61 --
Hannah BrendanCHIEF BUSINESS OFFICER AND COO $15k23.6k shares BuyAug 21, 2024 $0.63 --

News

seekingalpha.comQuince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcriptseekingalpha.comJun 11

seekingalpha.comQuince Therapeutics, Inc. (QNCX) M&A Call Prepared Remarks Transcriptseekingalpha.comMay 18

globenewswire.comUPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILDglobenewswire.comMay 18

globenewswire.comQuince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILDglobenewswire.comMay 18

globenewswire.comQuince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipelineglobenewswire.comMay 18

Trade QNCX

About Quince Therapeutics, Inc.

Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites. Leading their pipeline is NOV004, an anabolic peptide meticulously designed to pinpoint and accumulate its therapeutic action precisely at bone fracture locations. The company, previously known as Cortexyme, Inc., officially rebranded as Quince Therapeutics, Inc. in August 2022. Established in 2012, Quince Therapeutics is headquartered in South San Francisco, California.

CEO: Dirk Thye
IPO Date: May 9, 2019

Market Data

Open: $0.90
High: $0.9806
Low: $0.8923
Volume: 705.3K
Avg Volume: 4.9M
52W High: $45.50
52W Low: $0.79

Valuation

Market Cap: $5.3M
Enterprise Value: $-12M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-42M
Revenue: $0
Net Income: $-84M
Cash: $5.8M
Debt: $18M

Events

EarningsAug 11

EPS est. -0.6